Last --
Change Today 0.00 / 0.00%
Volume 0.0
All times are local (Market data is delayed by at least 15 minutes).

immuron ltd-spon adr (IMROY) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
149.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMURON LTD-SPON ADR (IMROY)

Related News

No related news articles were found.

immuron ltd-spon adr (IMROY) Related Businessweek News

No Related Businessweek News Found

immuron ltd-spon adr (IMROY) Details

Immuron Limited, a biopharmaceutical company, researches, develops, and sells polyclonal antibodies for the treatment and prevention of various diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. Its platform technology enables the development of medicines that target a range of medical needs, such as infectious diseases, immune mediated disorders, and cancers. The company commercializes its platform derived products through a range of regulatory pathways, including prescription, medical foods, over-the-counter medicines, and dietary supplements. It markets Travelan, a natural product to prevent infection by enterotoxigenic escherichia coli, which is the cause of travellers’ diarrhoea. The company is also developing IMM 124-E, a natural product for the treatment of fatty liver and non-alcoholic steatohepatitis/Type 2 diabetes, which is under Phase II clinical trial; IMM 529 for the treatment of clostridium difficile infection; IMM-363 to treat of side effects caused by chemotherapy or radiation; and IMM-160 to reduce tumour size and suppress liver cancer. Immuron Limited was founded in 1994 and is based in Southbank, Australia.

16 Employees
Last Reported Date: 08/29/14
Founded in 1994

immuron ltd-spon adr (IMROY) Top Compensated Officers

Interim Chief Executive Officer and Vice Pres...
Total Annual Compensation: A$220.0K
External Advisor
Total Annual Compensation: A$192.0K
Compensation as of Fiscal Year 2014.

immuron ltd-spon adr (IMROY) Key Developments

Immuron Ltd Enters Agreement with Linker Holdings Ltd for the Sale of Travelan in the People's Republic of China, Hong Kong and Macau

Immuron Ltd. has entered an agreement with Linker Holdings Ltd. for the sale of Travelan in the People's Republic of China, Hong Kong and Macau. Under the agreement, Linker has the exclusive rights to market, distribute and sell Travelan as a functional food and a dietary supplement in its licensed territory and has undertaken to contractually comply with specified annual minimum purchase obligations.

Immuron Ltd Enters an Agreement with Immune Biologies Pty Ltd for the Development and Commercialisation of IMM-124E for the Treatment of Short-Term Alcohol-Induced Liver Toxicity

Immuron Ltd. has entered an agreement with Immune Biologies Pty Ltd. for the development and commercialisation of IMM-124E for the treatment of short-term alcohol-induced liver toxicity. Under the agreement, Immune Biologies will carry out clinical trials designed to test the efficacy of IMM-124E for the prevention and/or treatment and/or amelioration of short-term alcohol-induced liver toxicity. The principle underlying these studies is that the anti-LPS activity of IMM-124E is the same underlying mechanism that governs the treatment of both non-alcoholic steatohepatitis (NASH) and alcoholic steatohepatitis (ASH), thus enabling the testing and use of IMM-124E in this third short-term clinical indication. Pending a successful outcome of the clinical trials to be undertaken by Immune Biologies, Immuron will sell the IMM-124E to Immune Biologies under a worldwide licence for the use of IMM-124E specifically for toxicity associated with short-term alcohol intake.

Immuron Limited Announces the Resignation of Amos Meltzer as Interim Chief Executive Officer

Immuron Limited announced that it has received a letter of resignation from its Interim Chief Executive Officer (CEO) Mr. Amos Meltzer. Mr. Meltzer has agreed to be available to assist beyond his 3-month notice period, if required, to facilitate a smooth transition to a new CEO.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMROY:US $0.00 USD 0.00

IMROY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMROY.
View Industry Companies
 

Industry Analysis

IMROY

Industry Average

Valuation IMROY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMURON LTD-SPON ADR, please visit www.immuron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.